NeoGenomics (NASDAQ:NEO) Issues FY 2025 Earnings Guidance

NeoGenomics (NASDAQ:NEO) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.150-0.190 for the period, compared to the consensus EPS estimate of 0.200. The company issued revenue guidance of $735.0 million-$745.0 million, compared to the consensus revenue estimate of $735.0 million.

Analysts Set New Price Targets

Several research firms have weighed in on NEO. The Goldman Sachs Group lowered their price target on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Bank of America decreased their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Jefferies Financial Group began coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price objective on the stock. Needham & Company LLC decreased their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Finally, Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.60.

NeoGenomics Trading Up 8.7 %

Shares of NASDAQ NEO opened at $10.15 on Thursday. The firm’s 50 day moving average price is $14.06 and its 200-day moving average price is $15.11. The company has a market cap of $1.30 billion, a PE ratio of -16.37 and a beta of 1.23. NeoGenomics has a 52-week low of $8.98 and a 52-week high of $19.11. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). The firm had revenue of $172.00 million during the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. On average, equities research analysts expect that NeoGenomics will post -0.2 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.